ClinicalTrials.gg
RecruitingNCT06916663Updated Apr 8, 2025

RCT Comparing Upper Body vs. Combined Exercise Protocols During Active Diabetic Foot Ulcer Treatment

An interventional study of Upper Body Exercise Protocol (UBE) and Combined Non-Weight Bearing Exercise Protocol (CE) in Diabetic Foot Ulcer, sponsored by Al Hayah University In Cairo. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Al Hayah University In Cairo · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Diabetic Foot with a site in Egypt — 7 open to participants now, 8 under way, none of them phase 3. Diabetic Foot · Egypt.

Planned enrollment
2nd of 26
153 · median 49
Started
2025
with 5 others
No phase
21 of 30
6 open now
Registered
23rd of 30
by date
Lead sponsor
1 of 30
Al Hayah University In Cairo

Among the 30 studies in Diabetic Foot with a site in Egypt, this one is the 2nd largest by planned enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2025, is one of 21 with no phase, and was the 23rd registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

7 of the 30 studies in Diabetic Foot with a site in Egypt are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Diabetic Foot with a site in Egypt, or all of them as a file.
02

Study summary

This randomized controlled trial (RCT) aims to evaluate the effectiveness of two different structured exercise interventions compared to standard care during active diabetic foot ulcer (DFU) treatment. Participants will be allocated to one of three groups: Upper Body Exercise (UBE), Combined Exercise (CE), or Standard Care Control (SC). The interventions are designed to improve cardiorespiratory fitness-as measured by changes in VO₂peak-and other secondary clinical, metabolic, vascular, inflammatory, muscular, and quality-of-life outcomes while ensuring proper offloading and wound management.

03

Conditions studied

  • Diabetic Foot Ulcer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age: Adults aged 18 years or older. Diagnosis: Confirmed diagnosis of Type 1 or Type 2 diabetes. Active DFU: Presence of a diabetic foot ulcer under active treatment, as documented by the wound care team.

Wound Stability: Ulcer size that meets protocol criteria (e.g., \<2 cm² or ≥2 cm²) and without critical limb ischemia.

Ability to Exercise: Medical clearance from a physician to safely participate in unsupervised upper body and non-weight bearing exercises.

Compliance: Capacity and willingness to adhere to the study protocol, including scheduled exercise sessions and offloading procedures.

Glycemic Control: Stable glycemic control medications regimen for at least 4 weeks prior to enrollment.

: Ability to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

Critical DFU Complications: Ulcers with signs of critical limb ischemia, severe infection (e.g., osteomyelitis), or wound deterioration that contraindicates participation.

Cardiovascular Limitations: Unstable cardiac conditions (e.g., uncontrolled arrhythmias, recent myocardial infarction within 6 months), severe heart failure, or any other condition contraindicating exercise.

Neurological or Musculoskeletal Limitations: Conditions that significantly impair upper body or core exercise performance (e.g., severe arthritis, recent upper body injury).

Cognitive Impairment: Significant cognitive or psychiatric disorders that would limit the ability to provide or adhere to the intervention protocol.

Concurrent Participation: Enrollment in another clinical trial or exercise program that conflicts with the study protocol.

Other Medical Risks: Any other condition, as determined by the study physician, that places the participant at increased risk of adverse events during exercise (e.g., severe peripheral vascular disease not amenable to offloading).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
153 participants (estimated)

Study arms

  • Experimental
    Upper Body Exercise Group (UBE):

    Structured upper extremity and core exercise sessions while maintaining foot offloading.

    Behavioral: Upper Body Exercise Protocol (UBE)

  • Experimental
    Combined Exercise Group (CE):

    Structured non-weight bearing combined exercise including upper body, core, and modified lower extremity exercises while maintaining foot offloading.

    Behavioral: Combined Non-Weight Bearing Exercise Protocol (CE)

  • Active comparator
    Standard Care Control Group (SC):

    Standard wound care without a structured exercise intervention.

    Behavioral: Standard Diabetic Foot Ulcer Wound Care (SC)

Interventions

  • BehavioralUpper Body Exercise Protocol (UBE)

    Participants randomized to the Upper Body Exercise Group will perform a structured, supervised exercise regimen focused exclusively on the upper extremities and core muscles, while rigorously maintaining foot offloading prescribed for diabetic foot ulcers (DFU). This intervention is delivered face-to-face in hospital-based outpatient rehabilitation centers. Sessions are held three times per week for 12 consecutive weeks (total 36 sessions), with each session lasting 45-60 minutes. Each UBE session comprises a 10-minute warm-up on an arm ergometer at 40-50% of the participant's heart rate reserve (HRR), followed by a circuit of eight upper body and core exercises.

  • BehavioralCombined Non-Weight Bearing Exercise Protocol (CE)

    Participants in the Combined Exercise Group will engage in a structured exercise regimen that integrates upper body, core, and modified lower extremity exercises-all performed in a non-weight bearing or seated position to ensure complete offloading of the affected foot. Sessions are conducted face-to-face in hospital-based rehabilitation centers. Participants attend three sessions per week for 12 weeks (36 sessions total), each lasting 45-60 minutes. Each session begins with a 10-minute warm-up on an arm ergometer at 40-50% HRR.

  • BehavioralStandard Diabetic Foot Ulcer Wound Care (SC)

    Participants assigned to the Standard Care Control Group will receive comprehensive DFU wound management in accordance with International Working Group on the Diabetic Foot (IWGDF) guidelines. This includes standard offloading strategies (using Total Contact Cast or removable cast walker), regular weekly wound assessments, and debridement if necessary. Diabetes management education is provided along with routine adjustments and monitoring of the offloading device to ensure proper healing support. No structured exercise intervention is added; however, all aspects of care such as continuous glucose monitoring and vascular assessments will be uniformly applied to allow comparison with the exercise groups.

06

What researchers measure

Primary outcomes

  1. Cardiorespiratory Fitness (VO₂peak)

    Change in VO₂peak measured using arm ergometry with validated protocols designed for patients with lower extremity limitations. VO₂peak is a key indicator of cardiovascular fitness, with improvements expected in response to the structured exercise interventions.

    Time frame: Baseline and at 12 weeks

Secondary outcomes

  1. Wound Healing - Percent Wound Area Reduction

    Reduction in wound area measured using digital planimetry. This quantifies improvement in wound healing by comparing wound sizes at different time point

    Time frame: 4, 8, and 12 weeks

  2. Wound Healing - Time to Wound Closure

    The duration in days from the start of the intervention until complete wound closure, determined through weekly assessments performed by the clinical team.

    Time frame: Recorded weekly during the 12-week intervention

  3. Wound Healing - Wound Recurrence Title

    Incidence of DFU recurrence in patients whose wounds have closed, providing an indicator of sustained wound healing.

    Time frame: At 6-month follow-up

  4. Metabolic Control - HbA1c Levels

    Glycated hemoglobin concentration measured from blood samples to assess long-term glycemic control, which is crucial for wound healing in DFU patients.

    Time frame: Baseline and 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Apr 2027, 24 months later.

Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 24 months is above that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 8, 2025
StartEst.
Apr 22, 2025
Primary completionEst.
Apr 23, 2027
CompletionEst.
Apr 23, 2027
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06916663
Lead sponsor
Al Hayah University In Cairo
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Apr 22, 2025 (estimated)
Primary completion
Apr 23, 2027 (estimated)
Completion
Apr 23, 2027 (estimated)
Last update
Apr 8, 2025

Study contacts

Ibrahim Zoheiry, Ph.D
Contact
ibrahim.alzoheiry@hotmail.com
01277774949
Mohamed ElMeligie, Ph.D
Contact
mohamed.elmeligie@ahuc.edu.eg

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion